je.st
news
Tag: pharmaceutical
Quebec pharmaceutical company Valeant has Q2 net profit as revenues jump
2014-07-31 18:39:30| Biotech - Topix.net
Valeant Pharmaceuticals International Inc., which is making a hostile takeover bid for Botox maker Allergan, posted a net profit of $126 million and saw its revenues jump.
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data For Oral Galectin-3 Inhibitor In Nonalcoholic Steatohepatitis (NASH)
2014-07-30 09:57:01| drugdiscoveryonline Home Page
La Jolla Pharmaceutical Company (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases,recently announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial
Tags: data
positive
oral
pharmaceutical
Davron Wins Contract for Batch Ovens for Pharmaceutical Manufacturer
2014-07-22 06:00:00| Industrial Newsroom - All News for Today
Chattanooga, Tenn. — Davron Technologies, Inc. has been selected by a leading pharmaceutical company to design and manufacture three batch drying ovens. The customer chose Davron because of the industrial oven solutions provider’s experience building ovens for the pharmaceutical industry and its level of commitment to quality in both the design and manufacturing of ovens. The batch ovens will be commissioned in the fall of 2014.<br /> <br /> The batch ovens are used to dry a ...This story is related to the following:Drying Ovens | Industrial Ovens
Tags: contract
manufacturer
wins
pharmaceutical
Pharmaceutical Customers In An Outsourcing Provider Merger -- Part 3 Of Interview With CEO of Newly Formed DPx Holdings B. V.
2014-07-01 16:39:27| drugdiscoveryonline Home Page
“They're so tired of me hammering them on customer metrics. I work on it every week, every site. I tell our workers, ‘You do this, and we'll get you the business.’” -- Jim Mullen This final article in our series featuring Jim Mullen, CEO of newly formed DPx Holdings B. V., discusses how to keep the focus on customers during M&A activity, and the broader transformation of sponsor–provider relationships in the pharmaceutical outsourcing industry. Earlier articles from our interview with Mullen dealt with how an acquisition comes together, and the importance of understanding the relationship between quality, capacity and job security for the early success of any M&A deal. In some ways, we’ve left the most important subject – customers – for last.
Gilead Submits New Drug Application to Japan's Pharmaceutical and...
2014-06-27 19:44:59| Biotech - Topix.net
Gilead Sciences, Inc. today announced that the company has submitted a New Drug Application to Japan's Pharmaceutical and Medical Devices Agency for approval of sofosbuvir, a once-daily nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus infection.
Tags: application
drug
pharmaceutical
submits
Sites : [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] next »